Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.

Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, Dorn GW 2nd, MacLennan DH, Kremastinos DT, Kranias EG.

J Clin Invest. 2003 Mar;111(6):869-76.

2.

Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy.

Haghighi K, Gregory KN, Kranias EG.

Biochem Biophys Res Commun. 2004 Oct 1;322(4):1214-22. Review.

PMID:
15336969
3.

A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.

Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, Fan GC, Tsiapras D, Parekh RR, Dorn GW 2nd, MacLennan DH, Kremastinos DT, Kranias EG.

Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1388-93. Epub 2006 Jan 23.

4.

The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase.

Haghighi K, Pritchard T, Bossuyt J, Waggoner JR, Yuan Q, Fan GC, Osinska H, Anjak A, Rubinstein J, Robbins J, Bers DM, Kranias EG.

J Mol Cell Cardiol. 2012 Mar;52(3):773-82. doi: 10.1016/j.yjmcc.2011.11.012. Epub 2011 Dec 1.

5.

Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban.

Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, Kranias EG, MacLennan DH, Seidman JG, Seidman CE.

Science. 2003 Feb 28;299(5611):1410-3.

6.

Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy.

Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK, Haghighi K, Seidman CE, Seidman JG, Dorn GW 2nd, Kranias EG.

J Clin Invest. 2003 Mar;111(6):859-67.

7.

A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids.

Haghighi K, Chen G, Sato Y, Fan GC, He S, Kolokathis F, Pater L, Paraskevaidis I, Jones WK, Dorn GW 2nd, Kremastinos DT, Kranias EG.

Hum Mutat. 2008 May;29(5):640-7. doi: 10.1002/humu.20692.

PMID:
18241046
8.

Sarcoplasmic reticulum Ca2+ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy.

Flesch M, Schwinger RH, Schnabel P, Schiffer F, van Gelder I, Bavendiek U, Südkamp M, Kuhn-Regnier F, Böhm M.

J Mol Med (Berl). 1996 Jun;74(6):321-32.

PMID:
8862513
9.

Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes.

Posch MG, Perrot A, Geier C, Boldt LH, Schmidt G, Lehmkuhl HB, Hetzer R, Dietz R, Gutberlet M, Haverkamp W, Ozcelik C.

Heart Rhythm. 2009 Apr;6(4):480-6. doi: 10.1016/j.hrthm.2009.01.016. Epub 2009 Jan 18.

PMID:
19324307
10.

Phospholamban as a therapeutic modality in heart failure.

Chu G, Kranias EG.

Novartis Found Symp. 2006;274:156-71; discussion 172-5, 272-6. Review.

PMID:
17019811
11.

Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition.

Schmitt JP, Ahmad F, Lorenz K, Hein L, Schulz S, Asahi M, Maclennan DH, Seidman CE, Seidman JG, Lohse MJ.

Circulation. 2009 Jan 27;119(3):436-44. doi: 10.1161/CIRCULATIONAHA.108.783506. Epub 2009 Jan 12.

12.

The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca2+-ATPase superinhibition and cardiac remodeling.

Zhao W, Yuan Q, Qian J, Waggoner JR, Pathak A, Chu G, Mitton B, Sun X, Jin J, Braz JC, Hahn HS, Marreez Y, Syed F, Pollesello P, Annila A, Wang HS, Schultz Jel J, Molkentin JD, Liggett SB, Dorn GW 2nd, Kranias EG.

Circulation. 2006 Feb 21;113(7):995-1004. Epub 2006 Feb 13.

13.

Mutations in the human phospholamban gene in patients with heart failure.

Medeiros A, Biagi DG, Sobreira TJ, de Oliveira PS, Negrão CE, Mansur AJ, Krieger JE, Brum PC, Pereira AC.

Am Heart J. 2011 Dec;162(6):1088-1095.e1. doi: 10.1016/j.ahj.2011.07.028. Epub 2011 Nov 8.

PMID:
22137083
14.

Deception in simplicity: hereditary phospholamban mutations in dilated cardiomyopathy.

Young HS, Ceholski DK, Trieber CA.

Biochem Cell Biol. 2015 Feb;93(1):1-7. doi: 10.1139/bcb-2014-0080. Epub 2014 Dec 1. Review.

PMID:
25563649
15.

Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy.

DeWitt MM, MacLeod HM, Soliven B, McNally EM.

J Am Coll Cardiol. 2006 Oct 3;48(7):1396-8. Epub 2006 Sep 12.

16.

Proteomic analysis of hyperdynamic mouse hearts with enhanced sarcoplasmic reticulum calcium cycling.

Chu G, Kerr JP, Mitton B, Egnaczyk GF, Vazquez JA, Shen M, Kilby GW, Stevenson TI, Maggio JE, Vockley J, Rapundalo ST, Kranias EG.

FASEB J. 2004 Nov;18(14):1725-7. Epub 2004 Sep 9.

17.

Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy.

Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR.

Cell. 1999 Oct 29;99(3):313-22.

18.

Hydrophobic imbalance in the cytoplasmic domain of phospholamban is a determinant for lethal dilated cardiomyopathy.

Ceholski DK, Trieber CA, Young HS.

J Biol Chem. 2012 May 11;287(20):16521-9. doi: 10.1074/jbc.M112.360859. Epub 2012 Mar 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk